The charts on this page feature a breakdown of the total annual pay for the top executives at ANI PHARMACEUTICALS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. ANI PHARMACEUTICALS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. ANI PHARMACEUTICALS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
James G. Marken
Senior Vice President, Operations and Product Development
Total Cash $695,876 Equity $1,025,632 Other $13,145 Total Compensation $1,734,653
Stephen P. Carey
Senior Vice President, Finance and Chief Financial Officer
Total Cash $1,085,319 Equity $1,743,585 Other $21,650 Total Compensation $2,850,554
Nikhil Lalwani
President and Chief Executive Officer
Total Cash $2,157,347 Equity $4,369,205 Other $14,508 Total Compensation $6,541,060
Christopher K. Mutz
Head of Rare Disease
Total Cash $585,944 Equity $1,010,757 Other $9,231 Total Compensation $1,605,932
Ori Gutwerg
Senior Vice President, Generics
Total Cash $710,744 Equity $808,593 Other $0 Total Compensation $1,519,337
For its 2021 fiscal year, ANI PHARMACEUTICALS INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Nikhil Lalwani CEO Pay $6,541,060 Median Employee Pay $50,403 CEO Pay Ratio 130:1
For its 2021 fiscal year, ANI PHARMACEUTICALS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Antonio R. Pera Total Cash $366,687
David B. Nash, M.D., M.B.A. Total Cash $384,187
Jeanne Thoma Total Cash $369,187
Patrick D. Walsh Total Cash $409,187
Robert E. Brown, Jr. Total Cash $384,187
Thomas J. Haughey Total Cash $389,187

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.